Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma (HCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact: Study coordinator (WeiZhang, MD) · weizhangtjh@hust.edu.cn · 086-13986029425

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Hepatocellular Carcinoma · Gastrointestinal Cancer Metastatic · Neuroendocrine Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Palo Alto, United States · Philadelphia, United States

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Seoul, South Korea